Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

Robert J. Kreitman, Philippe Moreau, Farhad Ravandi, Martin Hutchings, Anas Gazzah, Anne-Sophie Michallet, Zev A. Wainberg, Alexander Stein, Sascha Dietrich, Maja J. A. de Jonge, Wolfgang Willenbacher, Jacques De Grève, Evgeny Arons, Palanichamy Ilankumaran, Paul Burgess, Eduard Gasal, Vivek Subbiah

Blood (2023) 141 (9): 996–1006.

https://doi.org/10.1182/blood.2021013658

Published: 2023

Includes: Supplemental data

Journal Articles

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Blood (2022) 140 (Supplement 1): 7013–7015.

https://doi.org/10.1182/blood-2022-157963

Published: 2022

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Blood (2022) 140 (Supplement 1): 7007–7009.

https://doi.org/10.1182/blood-2022-159678

Published: 2022

Journal Articles

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Therese Aurran-Schleinitz, Cécile Tomowiak, Damien Roos-Weil, Emmanuelle Ferrant, Béatrice Mahé, Lysiane Molina, Loic Ysebaert, Luc Mathieu Fornecker, Anne-Sophie Michallet, Vincent Levy, Romain Guieze, Alain Delmer

Blood (2022) 140 (Supplement 1): 7030–7031.

https://doi.org/10.1182/blood-2022-163096

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Blood (2022) 140 (Supplement 1): 6631–6632.

https://doi.org/10.1182/blood-2022-159695

Published: 2022

Journal Articles

Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study

Loic Ysebaert, Xavier Troussard, Vincent Levy, Ronan Le Calloch, Romain Guieze, Kamel Laribi, Stephane Lepretre, Anne-Sophie Michallet, Véronique Leblond, Pierre Feugier, Elhem Lahjibi, Julien Ramier, Alain Delmer

Blood (2022) 140 (Supplement 1): 12395–12396.

https://doi.org/10.1182/blood-2022-162319

Published: 2022

Journal Articles

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

Michael Philippe, Jerome Guitton, Bertrand Favier, Clemence Santana, Emmanuelle Nicolas-Virelizier, Yann Guillermin, Anne-Sophie Michallet, Mauricette Michallet, Amine Belhabri

Blood (2022) 140 (Supplement 1): 6179–6180.

https://doi.org/10.1182/blood-2022-168327

Published: 2022

Journal Articles

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Arsène Vacherot, Emmanuel Beillard, Catherine Chassagne-Clément, Marie-Charlotte Laude, Pierre Sesques, Laure Lebras, Alexandra Traverse-Glehen, Claire Mauduit, Mauricette Michallet, Stéphane Morisset, Anne-Sophie Michallet, Yann Guillermin

Blood (2022) 140 (Supplement 1): 11878–11879.

https://doi.org/10.1182/blood-2022-169510

Published: 2022

Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer

Blood (2022) 140 (Supplement 1): 394–396.

https://doi.org/10.1182/blood-2022-159711

Published: 2022

Journal Articles

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Blood (2021) 138 (Supplement 1): 3570.

https://doi.org/10.1182/blood-2021-147467

Published: 2021

Journal Articles

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Blood (2021) 138 (Supplement 1): 3747.

https://doi.org/10.1182/blood-2021-149640

Published: 2021

Journal Articles

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Blood (2021) 138 (Supplement 1): 637.

https://doi.org/10.1182/blood-2021-152515

Published: 2021

Journal Articles

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

Blood (2021) 138 (Supplement 1): 641.

https://doi.org/10.1182/blood-2021-145624

Published: 2021

Journal Articles

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 2526.

https://doi.org/10.1182/blood-2021-145440

Published: 2021

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Blood (2021) 137 (8): 1019–1023.

https://doi.org/10.1182/blood.2020008164

Published: 2021

Includes: Supplemental data

Journal Articles

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Amine Belhabri, MD, Liliana Vila, MD, Mael Heiblig, Stephane Morisset, BioStat, Emmanuelle Nicolas-Virelizier, MD, Clémence Santana, MD, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Anne-Sophie Michallet, MD PhD, Philippe Rey, MD, Yann Guillermin, MD, Souad Assad, MD, Laure Lebras, MD, Mauricette Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142956

Published: 2020

Journal Articles

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Romain Guieze, MD, Loic Ysebaert, MD PhD, Lysiane Molina, MD, Damien Roos-Weil, MDPhD, Anne-Sophie Michallet, MD PhD, Benedicte Hivert, MD, Julie Gay, MD, Alain Saad, MD, Luc Mathieu Fornecker, MD PhD, Julien Broséus, Valérie Rouille, Laëtitia Auvray, Alain Jacques Delmer, MD PhD, Pierre Feugier, MD PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-136667

Published: 2020

Journal Articles

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Mauricette Michallet, MD PhD, Romain Buono, PharmD, Mohamad Sobh, PharmD, Solene Poirey, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, MD, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Aude Flechon, MD PhD, Helen Boyle, MD, Franck E Nicolini, MDPhD, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142355

Published: 2020

Journal Articles

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Loic Ysebaert, MD PhD, Anne-Sophie Michallet, MD PhD, Fontanet Bijou, MD, Aline Clavert, MD, Anne Quinquenel, MD, Anne Calleja, Romain Guieze, MD PhD, Emmanuelle Ferrant, MD, Annie Brion, Kamel Laribi, MD

Blood (2019) 134 (Supplement_1): 1741.

https://doi.org/10.1182/blood-2019-122318

Published: 2019

NARROW

Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the Icll-07 Filo Trial

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with TP53 Aberrations: Results of the Filo Phase II Study IDA53

Blinatumomab for Patients with Richter Syndrome: Final Results of the Phase 2 Blinart Trial from the Filo Group

Real-World Efficacy and Safety of Venetoclax Alone and in Combination with Rituximab in Patients with Chronic Lymphocytic Leukemia: Interim Results of the Verone Study

Venetoclax Pharmacokinetics in Real World AML Patients: A Real Candidate for Therapeutic Drug Monitoring

A Genomic Approach in High-Grade B Cell Lymphoma with MYC and BCL2 and / or BCL6 Rearrangements: Two Clusters Stood out on Next Generation Sequencing Results

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group

Safety and Efficacy of Venetoclax-Based Treatment in Elderly CLL Patients: A Retrospective Study from the Filo Group

Humoral Response to mRNA Vaccines BNT162b2 and mRNA-1273 COVID-19 in Chronic Lymphocytic Leukemia Patients

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR

High Frequency of CNS Involvement in Transformed Waldenström Macroglobulinemia

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial

Characteristics and Outcomes of Therapy-Related Acute Myeloid Leukemia: Results of Retrospective Analysis of 116 Adult Patients

Blinatumomab after R-CHOP Debulking Therapy for Patients with Richter Transformation: Preliminary Results of the Multicenter Phase 2 Blinart Trial from the Filo Group

Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program

Real-World Ibrutinib Validation of the Ball Score to Predict Overall Survival: A Filo Group Study in RR CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only